248 related articles for article (PubMed ID: 21672506)
1. [Psychopharmocotherapy of schizophrenia in forensic and general psychiatry].
Stompe T; Schanda H
Neuropsychiatr; 2011; 25(2):75-84. PubMed ID: 21672506
[TBL] [Abstract][Full Text] [Related]
2. [French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].
Samalin L; Abbar M; Courtet P; Guillaume S; Lancrenon S; Llorca PM
Encephale; 2013 Dec; 39 Suppl 4():189-203. PubMed ID: 24373464
[TBL] [Abstract][Full Text] [Related]
3. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
Bret P; Bret MC; Queuille E
Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of concomitant oral antipsychotic drug use among patients treated with long-acting, intramuscular, antipsychotic medications.
Aggarwal NK; Sernyak MJ; Rosenheck RA
J Clin Psychopharmacol; 2012 Jun; 32(3):323-8. PubMed ID: 22544006
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome.
Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM
J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343
[TBL] [Abstract][Full Text] [Related]
6. [Intervals between hospitalisations in schizophrenia patients under antipsychotics in depot-form versus oral second generation antipsychotics].
Gutwinski S; Müller P; Koller M
Psychiatr Prax; 2007 Sep; 34(6):289-91. PubMed ID: 17806015
[TBL] [Abstract][Full Text] [Related]
7. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
8. Substance abuse and the management of medication nonadherence in schizophrenia.
Wilk J; Marcus SC; West J; Countis L; Hall R; Regier DA; Olfson M
J Nerv Ment Dis; 2006 Jun; 194(6):454-7. PubMed ID: 16772865
[TBL] [Abstract][Full Text] [Related]
9. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
[TBL] [Abstract][Full Text] [Related]
10. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
Schanda H; Stompe T
Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
[TBL] [Abstract][Full Text] [Related]
11. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
Kane JM; Leucht S; Carpenter D; Docherty JP;
J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
[TBL] [Abstract][Full Text] [Related]
12. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
13. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
[TBL] [Abstract][Full Text] [Related]
14. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands.
Pechlivanoglou P; Vehof J; van Agthoven M; de Jong-van den Berg LT; Postma MJ
Clin Ther; 2010 Jan; 32(1):108-18. PubMed ID: 20171417
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
[TBL] [Abstract][Full Text] [Related]
16. Risks versus benefits of different types of long-acting injectable antipsychotics.
McEvoy JP
J Clin Psychiatry; 2006; 67 Suppl 5():15-8. PubMed ID: 16822092
[TBL] [Abstract][Full Text] [Related]
17. Concurrent Oral Antipsychotic Drug Use Among Schizophrenia Patients Initiated on Long-Acting Injectable Antipsychotics Post-Hospital Discharge.
Doshi JA; Pettit AR; Stoddard JJ; Zummo J; Marcus SC
J Clin Psychopharmacol; 2015 Aug; 35(4):442-6. PubMed ID: 26075492
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
19. Treatment adherence in schizophrenia and schizoaffective disorder.
Goff DC; Hill M; Freudenreich O
J Clin Psychiatry; 2011 Apr; 72(4):e13. PubMed ID: 21527119
[TBL] [Abstract][Full Text] [Related]
20. Improving treatment adherence in patients with schizophrenia.
Kane JM
J Clin Psychiatry; 2011 Sep; 72(9):e28. PubMed ID: 21951990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
